Positive News Sentiment NASDAQ:RPHM Reneo Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.83 -0.08 (-2.75%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$2.73▼$3.0850-Day Range$1.96▼$2.9152-Week Range$1.92▼$11.40Volume75,993 shsAverage Volume122,577 shsMarket Capitalization$69.22 millionP/E RatioN/ADividend YieldN/APrice Target$26.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Reneo Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside847.0% Upside$26.80 Price TargetShort InterestHealthy3.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.47) to ($2.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.17 out of 5 starsMedical Sector300th out of 1,433 stocksPharmaceutical Preparations Industry135th out of 683 stocks 3.5 Analyst's Opinion Consensus RatingReneo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.80, Reneo Pharmaceuticals has a forecasted upside of 847.0% from its current price of $2.83.Amount of Analyst CoverageReneo Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.43% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently decreased by 4.44%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPHM. Previous Next 3.7 News and Social Media Coverage News SentimentReneo Pharmaceuticals has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Reneo Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest2 people have searched for RPHM on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders15.40% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.53% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to decrease in the coming year, from ($2.47) to ($2.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Reneo PharmaceuticalsReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More RPHM Stock News HeadlinesJune 30, 2022 | finance.yahoo.comReneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)June 20, 2022 | finance.yahoo.comIs Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Invest In Growth?July 7, 2022 | Investing Trends (Ad)Is the US Military Secretly Under Chinese Control?Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...May 10, 2022 | seekingalpha.comReneo Pharmaceuticals GAAP EPS of -$0.53 misses by $0.01May 10, 2022 | finance.yahoo.comReneo Pharmaceuticals Reports First Quarter 2022 Financial ResultsMarch 23, 2022 | seekingalpha.comReneo Pharmaceuticals GAAP EPS of -$0.43 beats by $0.14March 23, 2022 | finance.yahoo.comReneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateMarch 7, 2022 | seekingalpha.comReneo Pharmaceuticals promotes Michael Cruse to COO roleJuly 7, 2022 | Investing Trends (Ad)Is the US Military Secretly Under Chinese Control?Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...February 2, 2022 | finance.yahoo.comReneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare ConferenceJanuary 24, 2022 | finance.yahoo.comReneo Pharmaceuticals Announces Changes to its Board of DirectorsJanuary 10, 2022 | nasdaq.comWe Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business GrowthDecember 24, 2021 | nasdaq.comReneo Pharmaceuticals Inc Shares Close the Day 13.0% Higher - Daily WrapDecember 16, 2021 | benzinga.comCathie Wood Sells $8.6M Worth Shares In Pfizer, Buys Coinbase And Robinhood On The DipNovember 11, 2021 | finance.yahoo.comReneo Pharmaceuticals Reports Third Quarter 2021 Financial ResultsNovember 1, 2021 | benzinga.comReneo Pharmaceuticals to Participate at Upcoming Investor ConferencesOctober 14, 2021 | finance.yahoo.comReneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001October 11, 2021 | finance.yahoo.comHere's What Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) Shareholder Ownership Structure Looks LikeOctober 11, 2021 | finance.yahoo.comReneo Pharmaceuticals Appoints Ashley Hall as Chief Development OfficerSeptember 10, 2021 | nasdaq.comA Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) insider lowered their holding by 100% earlier this yearSeptember 9, 2021 | benzinga.comReneo Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 11, 2021 | finance.yahoo.comReneo Pharmaceuticals Reports Second Quarter 2021 Financial ResultsJuly 30, 2021 | seekingalpha.comDosing underway in Reneo Pharma's mid-stage STRIDE studyJuly 28, 2021 | finance.yahoo.comReneo Pharmaceuticals Announces First Patient Dosed in the STRIDE StudyJuly 18, 2021 | barrons.comReneo Pharmaceuticals Inc.July 16, 2021 | nasdaq.comFriday 7/16 Insider Buying Report: RPHM, CAGJuly 12, 2021 | finance.yahoo.comWe're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn RateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees24Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/07/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$26.80 High Stock Price Forecast$45.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+847.0%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.08% Return on Assets-28.83% Debt Debt-to-Equity RatioN/A Current Ratio18.04 Quick Ratio18.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.03 per share Price / Book0.47Miscellaneous Outstanding Shares24,460,000Free Float20,692,000Market Cap$69.22 million OptionableNot Optionable Beta0.56 Reneo Pharmaceuticals Frequently Asked Questions Should I buy or sell Reneo Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Reneo Pharmaceuticals stock. View analyst ratings for Reneo Pharmaceuticals or view top-rated stocks. What is Reneo Pharmaceuticals' stock price forecast for 2022? 5 Wall Street research analysts have issued 12 month target prices for Reneo Pharmaceuticals' shares. Their RPHM stock forecasts range from $15.00 to $45.00. On average, they predict Reneo Pharmaceuticals' share price to reach $26.80 in the next twelve months. This suggests a possible upside of 847.0% from the stock's current price. View analysts' price targets for Reneo Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Reneo Pharmaceuticals' stock price performed in 2022? Reneo Pharmaceuticals' stock was trading at $8.55 on January 1st, 2022. Since then, RPHM shares have decreased by 66.9% and is now trading at $2.83. View the best growth stocks for 2022 here. When is Reneo Pharmaceuticals' next earnings date? Reneo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Reneo Pharmaceuticals. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) posted its earnings results on Tuesday, May, 10th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.01. View Reneo Pharmaceuticals' earnings history. Who are Reneo Pharmaceuticals' key executives? Reneo Pharmaceuticals' management team includes the following people: Mr. Michael G. Grey, Founder & Exec. Chairman (Age 69)Mr. Gregory J. Flesher, Pres, CEO & Director (Age 52, Pay $743.05k) (LinkedIn Profile)Mr. Michael P. Cruse, Chief Operating Officer (Age 50, Pay $423.3k) (LinkedIn Profile)Mr. Vineet R. Jindal, Consultant (Age 44, Pay $568.27k) (LinkedIn Profile)Ms. Jennifer P. Lam, Principal Financial & Accounting OfficerMs. Wendy S. Johnson M.B.A., Consultant (Age 70)Dr. Alejandro Dorenbaum, Chief Medical Officer (Age 61)Ms. Lynn Purkins Ph.D., Sr. VP of Clinical OperationsMs. Ashley F. Hall J.D., Chief Devel. Officer (Age 50) Who are some of Reneo Pharmaceuticals' key competitors? Some companies that are related to Reneo Pharmaceuticals include Biotech Acquisition (BIOT), CytoDyn (CYDY), Aadi Bioscience (AADI), Alpine Immune Sciences (ALPN), Sernova (SEOVF), LianBio (LIAN), Verona Pharma (VRNA), G1 Therapeutics (GTHX), Provention Bio (PRVB), CymaBay Therapeutics (CBAY), Theseus Pharmaceuticals (THRX), XOMA (XOMA), Rallybio (RLYB), PepGen (PEPG) and InterCure (INCR). View all of RPHM's competitors. When did Reneo Pharmaceuticals IPO? (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO. What is Reneo Pharmaceuticals' stock symbol? Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM." How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Reneo Pharmaceuticals' stock price today? One share of RPHM stock can currently be purchased for approximately $2.83. How much money does Reneo Pharmaceuticals make? Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $69.22 million. The company earns $-39,770,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. How many employees does Reneo Pharmaceuticals have? Reneo Pharmaceuticals employs 24 workers across the globe. How can I contact Reneo Pharmaceuticals? The official website for Reneo Pharmaceuticals is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com. This page (NASDAQ:RPHM) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
